在ST升高心肌梗塞后左心室喷射分数减少,接受初级皮肤冠状动脉干预的患者中使用empagliflozin和colchicine:一种随机,双盲,三臂并行组,受控试验的研究方案
Sajad Khiali1, Mohammadreza Taban-Sadeghi2, Parvin Sarbakhsh3
1Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Trials
|October 6, 2023
概括
这项研究研究了对非糖尿病患者的empagliflozin和colchicine,这些患者患有心肌梗塞后心肌梗塞,排泄率降低. 它旨在改善心血管结果并降低心力衰竭风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 患有急性心肌梗塞的患者面临慢性心力衰竭和死亡的高风险.
- 有限的证据表明,-葡萄糖共运输体-2 抑制剂对非糖尿病患者心血管后心肌梗塞和减少射出分数的心血管后果是有限的.
- 恩帕格利弗洛辛和胆固醇,或高剂量恩帕格利弗洛辛的联合作用在这个患者群体中仍然未被评估.
研究的目的:
- 评估早期使用empagliflozin (标准剂量和高剂量) 以及empagliflozin和colchicine组合治疗的疗效和安全性.
- 评估这些治疗对纽约心脏协会功能分类和高灵敏性C反应蛋白水平的影响.
- 探索ST升高心肌梗塞后排气分数减少的非糖尿病患者的新型治疗策略.
主要方法:
- 一个前性,双盲,安慰剂控制的随机试验,涉及105名患者.
- 随机分配了ST升高后心肌梗塞左心室喷射分数减少 (≤40%) 的患者.
- 治疗臂包括每天10毫克的empagliflozin,每天10毫克的empagliflozin加上每天两次0.5毫克的胆固醇或每天25毫克的empagliflozin,持续12周.
主要成果:
- 主要结局包括纽约心脏协会功能分类和高灵敏度C反应蛋白在4周和12周的变化.
- 该研究将提供有关不同剂量的empagliflozin和组合疗法的比较有效性的数据.
- 将评估研究治疗方案的安全性.
结论:
- 这项试验是首次检查标准剂量empagliflozin和colchicine以及高剂量empagliflozin的组合,用于非糖尿病患者的心肌梗塞后心肌梗塞减少排泄率.
- 预计这些发现将大大提高这种脆弱患者群体的治疗策略.
- 结果将为临床实践提供有关早期治疗干预措施的信息,以减轻不良心血管事件.
关键词:
临床试验临床试验是指临床试验的临床试验.科尔奇辛 (Colchicine) 是一种可口药.恩帕格利弗洛辛 (Empagliflozin) 是一种非常重要的药物.心脏衰竭是因为心脏衰竭.这是一个LVSDSD.心肌梗塞的心脏病发作更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.5K
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.3K
相关概念视频
01:30Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
01:17Pericarditis III: Medical Management
13
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
13
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
01:28Cardiac Catheterization I: Pre-Procedure Overview
38
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
38
01:28Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
445
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
445